14.09.22
The only Innovation Center for the production of vaccines in Central Asia will open in the Tashkent region. The cost of the project is $ 100 million.
On the eve of September 13, within the framework of the SCO summit in Samarkand, the Ministry of Innovation together with Luye Investment Group Co., Ltd signed a memorandum on the establishment of an Innovation center for the production of vaccines in the Tashkent region, the press service of the ministry reports. At the meeting, the Ministry of Innovative Development together with the company signed a memorandum on the establishment of a Center for Innovative Vaccines with a total cost of $ 100 million in 2023-2028. Also, the official representative of the company Liu Tianko highly appreciated the work carried out by the Ministry of Innovative Development of Uzbekistan on the creation and production of a coronavirus vaccine.
“The Innovative Vaccine Center is the only full-cycle biotechnological research and development enterprise in Central Asia, which allows delivering high-tech products to the market of the country and the CIS countries. The project provides for the production of 200 million doses of 10 types of vaccines against hepatitis A, hepatitis B, papilloma, measles, tetanus and other diseases in the amount of $2 billion per year," the report says.
